Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
BackgroundDeveloping prediction tools for immunotherapy approaches is a clinically important and rapidly emerging field. The routinely used prediction biomarker is inaccurate and may not adequately utilize large amounts of medical data. Machine learning is a promising way to predict the benefit of i...
Main Authors: | Zhichao Liu, Guo Lin, Zeping Yan, Linduo Li, Xingchen Wu, Jingrong Shi, Jianxing He, Lei Zhao, Hengrui Liang, Wei Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.989275/full |
Similar Items
-
Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
by: Luigi Della Gravara, et al.
Published: (2021-06-01) -
TMB in NSCLC: A Broken Dream?
by: Sara Bravaccini, et al.
Published: (2021-06-01) -
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
by: Antonio Santaniello, et al.
Published: (2019-09-01) -
Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma
by: Yuhong Huang, et al.
Published: (2024-02-01) -
Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
by: Rui-Yan Wu, et al.
Published: (2023-01-01)